Apolipoprotein A-I and risk for cardiovascular diseases

Current Atherosclerosis Reports

Volumn 8, Issue 5, 2006, Pages 365-373

  Khuseyinova, Natalie ^b   Koenig, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESTYRAMINE; D 4F; ETC 216; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PRAVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL OBSERVATION; CLINICAL PRACTICE; CLINICAL TRIAL; ENZYME INHIBITION; HEART INFARCTION; HEART PROTECTION; HUMAN; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION;

APOLIPOPROTEIN A-I; CARDIOVASCULAR DISEASES; HUMANS; PROGNOSIS; RISK FACTORS;

EID: 33748431081     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-006-0033-9     Document Type: Review

References (51)

1. Wilson PW, Abbott RD, Castelli WP: High density cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988, 8:737-741.
2. Castelli WP, Garrison RJ, Wilson PW, et al.: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986, 256:2835-2838.
3. Gordon DJ, Probstfield JL, Garrison RJ, et al.: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
4. Ansell BJ, Watson KE, Fogelman AM, et al.: High-density lipoprotein function recent advances. J Am Coll Cardiol 2005, 46:1792-1798.
5. Calabresi L, Gomaraschi M, Franceschini G: Endothelial protection by high-density lipoproteins: from bench to bed-side. Arterioscler Thromb Vasc Biol 2003, 23:1724-1731.
6. Rye KA, Barter PJ: Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004, 24:421-428.
7. Lewis GF, Rader DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005, 96:1221-1232.
8. Lee JY, Parks JS: ATP-binding cassette transporter AI and its role in HDL formation. Curr Opin Lipidol 2005, 16:19-25.
9. Walldius G, Jungner I: The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 2006, 259:493-519.
10. Maciejko JJ, Holmes DR, Kottke BA, et al.: Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med 1983, 309:385-389.
11. Moss AJ, Goldstein RE, Marder VJ, et al.: Thrombogenic factors and recurrent coronary events. Circulation 1999, 99:2517-2522.
12. Bolibar I, von Eckardstein A, Assmann G, Thompson S; ECAT Angina Pectoris Study Group: Short-term prognostic value of lipid measurements in patients with angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities. Thromb Haemost 2000, 84:955-960.
13. Schlitt A, Blankenberg S, Bickel C, et al.: Prognostic value of lipoproteins and their relation to inflammatory markers among patients with coronary artery disease. Int J Cardiol 2005, 102:477-485.
14. Thompson A, Danesh J: Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006, 259:481-492.
15. Stampfer MJ, Sacks FM, Salvini S, et al.: A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction. N Engl J Med 1991, 325:373-381.
16. Lamarche B, Moorjani S, Lupien PJ, et al.: Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996, 94:273-278.
17. Sharrett AR, Ballantyne CM, Coady SA, et al., Atherosclerosis Risk in Communities Study Group: Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001, 104:1108-1113.
18. Talmud PJ, Hawe E, Miller GJ, et al.: Non-fasting apolipoprotein B and triglycerides levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002, 22:1918-1923.
19. Meisinger C, Loewel H, Mraz W, Koenig W: Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 2005, 26:271-278.
20. Luc G, Bard JM, Ferrieres J, et al.: Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 2002, 22:1155-1161.
21. Walldius G, Jungner I, Holme I, et al.: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358:2026-2033.
22. Ridker PM, Rifai N, Cook NR, et al.: Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005, 294:326-333.
23. Gotto AM, Whitney E, Stein EA, et al.: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS). Circulation 2000, 101:477-484.
24. Simes RJ, Marschner IC, Hunt D, et al.: Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in the Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002, 105:1162-1169.
25. van Lennep JE, Westerveld HT, van Lennep HW, et al.: Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 2000, 20:2408-2413.
26. Packard CJ, Ford I, Robertson M, et al.: PROSPER Study Group: Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2005, 112:3058-3065.
27. Walldius G, Aastveit AH, Jungner I: Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 2006, 259:259-266.
28. Shahar E, Chambless LE, Rosamond WD, et al.: Atherosclerosis Risk in Communities Study. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003, 34:623-631.
29. Marcovina S, Packard CJ: Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med 2006, 259:437-446.
30. Marcovina SM, Albers JJ, Henderson LO, Hannon WH: International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993, 39:773-781.
31. Shepherd J: Raising HDL-cholesterol and lowering CHD risk: does intervention work? Eur Heart J 2005 (Suppl 7): F15-F22.
32. Meyers CD, Kashyap ML: Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. Curr Opin Cardiol 2005, 20:307-312.
33. Klerkx AH, de Grooth GJ, Zwinderman AH, et al.: Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 2004, 34:21-28.
34. Martin G, Duez H, Blanquart C, et al.: Statin-induced inhibition of the Rho-signaling pathway activates PPAR-alpha and induces HDL apoA-I. J Clin Invest 2001, 107:1423-1432.
35. Maejima T, Yamazaki H, Aoki T, et al.: Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 2004, 324:835-839.
36. Chinetti-Gbaguidi G, Fruchart JC, Staels B: Pleiotropic effects of fibrates. Curr Atheroscler Rep 2005, 7:396-401.
37. van Wijk JP, Rabelink TJ. Impact of thiazolidinedione therapy on atherogenesis. Curr Atheroscler Rep 2005, 7:369-374.
38. Szapary PO, Bloedon LT, Samaha FF, et al.: Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006, 26:182-188.
39. Chinetti G, Lestavel S, Bocher V, et al.: PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001, 7:53-58.
40. Rosenson RS: Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 2003, 171:87-96.
41. Kazi D, Farmer JA: Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary. Curr Atheroscler Rep 2005, 7:88-94.
42. Sirtori CR, Calabresi L, Franceschini G, et al.: Cardiovascular status of carriers of the apolipoprotein A-I (Milano) mutant: the Limone sul Garda study. Circulation 2001, 103:1949-1954.
43. Calabresi L, Sirtori CR, Paoletti R, Franceschini G: Recombinant apolipoprotein A-I Milano for the treatment of cardiovascular diseases. Curr Atheroscler Rep 2006, 8:163-167.
44. Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
45. Nicholls SJ, Tuzcu EM, Sipahi I, et al.: Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol 2006, 4:992-997.
46. Navab M, Anantharamaiah GM, Reddy ST, et al.: Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 2005, 25:1325-1331.
47. Navab M, Anantharamaiah GM, Hama S, et al.: Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002, 105:290-292.
48. Navab M, Anantharamaiah GM, Hama S, et al.: D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005, 25:1426-1432.
49. Forrester JS, Makkar R, Shah PK: Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 2005, 111:1847-1854.
50. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al.: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002, 105:2159-2165.
51. Brousseau ME, Schaefer EJ, Wolfe ML, et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350:1505-1515.